

November 22, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Growth)

Shinya Kurebayashi, President & CEO

Announcement of the launch of Pegfilgrastim biosimilar

Tokyo, November 22, 2023 – Kidswell Bio Corporation (“KWB”) has been collaborating with Mochida Pharmaceutical Co., Ltd. based on the joint development agreement for the biosimilar in the oncology (Project name: GBS-010, Pegfilgrastim biosimilar) executed on December 5, 2016, and Pegfilgrastim biosimilar Mochida from Mochida Pharmaceutical Co., Ltd. and Pegfilgrastim biosimilar Nipro from Nipro Corporation have started launching today.

As the first biosimilar of pegfilgrastim in Japan, KWB believes that it will expand therapeutic options for patients, improve their QOL, and contribute to reducing economic burdens.

It is KWB’s fourth product to launch in the biosimilar business following Filgrastim BS, Darbepoetin Alpha BS and Ranibizumab BS. Besides the revenues from these biosimilars, by leveraging the know-how and expertise about biotechnology acquired in the past business activities, KWB will continue focusing on the accomplishment of the medium-term strategic plan, KWB 2.0, and further business growth.

The impact on the KWB’s business and financial situation is expected to be minimal.

Reference

Press release from Mochida Pharmaceutical Co., Ltd.

URL: <https://www.mochida.co.jp/news/>

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under “Kids Well, All Well.”

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com